#United States #Seattle #Healthcare Innovation #A1C Testing #Orange Biomed

Orange Biomed's Breakthrough in Diabetes Testing

Orange Biomed, a pioneering healthcare company, has created waves in the medical community with its groundbreaking microfluidic technology, designed for enhanced accessibility and precision in diabetes management. This innovative approach has catapulted them onto Fortune Korea's prestigious "Top 40 Emerging South Korean Healthcare Innovations" list, showcasing their advancing presence in the United States healthcare realm.

The company's flagship product, the OBM rapid A1C, represents a significant leap forward in diabetes monitoring. This pocket-sized device is the first of its kind to measure glycated hemoglobin (A1C) levels without the need for traditional lab settings. The easy-to-use design aims to eliminate common obstacles faced by many diabetes patients, facilitating consistent and convenient testing.

Experts in the field, including a panel from the renowned consulting firm BDMT Global, have lauded Orange Biomed for its initiative in addressing unfulfilled needs within the U.S. healthcare system. According to evaluators, "The OBM rapid A1C could transform how diabetes patients monitor their condition by removing the logistical and cost barriers of lab-based testing." This sentiment underscores the device's potential to democratize diabetes care, making it more attainable for those affected by the condition.

Orange Biomed's commitment to improving healthcare extends beyond their product development. They have actively launched the "M.A.P. YOUR HEALTH" campaign, whereby they collaborate with health organizations and community groups in Chicago to promote chronic disease prevention awareness and broaden access to necessary healthcare services. Yeaseul Park, CEO and co-president of the company, expressed that this recognition serves as an affirmation of their mission to innovate in global healthcare. "Being named to the Top 40 is more than an honor—it's proof that our technology can make a real impact in the U.S. healthcare system," she stated. She further emphasized the importance of building robust partnerships and transforming these opportunities into tangible impacts in healthcare.

Backed by over $7.5 million in funding and numerous awards for innovation, Orange Biomed has showcased their advancements at prominent U.S. healthcare forums like the American Diabetes Association's Innovation Hub and the Diabetes Technology Meeting (DTM). They are also actively engaging with professional networks such as ADLM and ADCES to bolster their standing in the community.

As part of their strategic planning, the company is preparing to submit a request for 510(k) clearance to the FDA, allowing for the potential distribution and regulation of their pioneering product. This step marks a critical milestone in their journey towards widespread accessibility of diabetes care solutions.

For additional insights and updates, interested individuals are encouraged to visit www.orangebiomed.com or connect with Orange Biomed across major social media platforms, including LinkedIn, Instagram, Facebook, and YouTube. Their continuous efforts highlight a dedicated drive towards advancing healthcare technology and addressing critical health challenges faced by diabetes patients across the globe.